Active Lipid Management In Coronary Artery Disease (ALMICAD) Study Sanjaya Khanal, MD, Omar Obeidat, MD, Michael P. Hudson, MD, Mouaz Al-Mallah, MD, Mary Bloome, PharmD, Mei Lu, PhD, Adam B. Greenbaum, MD, Aaron D. Kugelmass, MD, W. Douglas Weaver, MD The American Journal of Medicine Volume 120, Issue 8, Pages 734.e11-734.e17 (August 2007) DOI: 10.1016/j.amjmed.2006.06.048 Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 1 Screening, enrollment, and follow-up. The American Journal of Medicine 2007 120, 734.e11-734.e17DOI: (10.1016/j.amjmed.2006.06.048) Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 2 Lipid clinic algorithm. FLPP=fasting lipid profile; ALT=alanine aminotransferase; D/C=discontinue; LDL=LDL cholesterol. %Statins: May substitute simvastatin with atorvastatin or pravastatin at equivalent doses. #Niacin (long acting): Start with 500 mg/d and increase as tolerated to 3 g/d. +Fibrates: fenofibrate 67 mg/d to maximum 200 mg/d; may substitute gemfibrozil 600 mg twice daily. ∧Bile acids: colesevelam 625 mg, 3 tablets twice per day with meals; may substitute cholestyramine or colestipol 2 to 6 scoops twice daily with meals. The American Journal of Medicine 2007 120, 734.e11-734.e17DOI: (10.1016/j.amjmed.2006.06.048) Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 3 Comparison of clinical outcomes at 2 years (%) between the groups. MACE=major adverse cardiac events, MI=myocardial infarction, PCI=percutaneous coronary intervention, CABG=coronary bypass surgery. The American Journal of Medicine 2007 120, 734.e11-734.e17DOI: (10.1016/j.amjmed.2006.06.048) Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 4 Kaplan-Meier major cardiovascular event-free survival curves. MACE=major adverse cardiac events. The American Journal of Medicine 2007 120, 734.e11-734.e17DOI: (10.1016/j.amjmed.2006.06.048) Copyright © 2007 Elsevier Inc. Terms and Conditions